bavituximab

Ligand id: 8002

Name: bavituximab

References
1. DeRose P, Thorpe PE, Gerber DE. (2011)
Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment.
Immunotherapy, 3 (8): 933-44. [PMID:21843081]
2. Ran S, Downes A, Thorpe PE. (2002)
Increased exposure of anionic phospholipids on the surface of tumor blood vessels.
Cancer Res., 62 (21): 6132-40. [PMID:12414638]
3. Thorpe PE. (2004)
Vascular targeting agents as cancer therapeutics.
Clin. Cancer Res., 10 (2): 415-27. [PMID:14760060]
4. Thorpe PE. (2010)
Targeting anionic phospholipids on tumor blood vessels and tumor cells.
Thromb. Res., 125 Suppl 2: S134-7. [PMID:20433993]
5. Yin Y, Huang X, Lynn KD, Thorpe PE. (2013)
Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation.
Cancer Immunol Res, 1 (4): 256-68. [PMID:24777853]